Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

36.31
+0.34500.96%
Pre-market: 36.700.3950+1.09%05:12 EDT
Volume:1.29M
Turnover:46.39M
Market Cap:6.89B
PE:-12.61
High:36.35
Open:35.20
Low:35.13
Close:35.96
Loading ...

BridgeBio Pharma's Beyonttra Approved in UK for Heart Condition due to Amyloidosis

MT Newswires Live
·
31 mins ago

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

GlobeNewswire
·
1 hour ago

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

GlobeNewswire
·
22 Apr

BridgeBio price target raised to $53 from $49 at H.C. Wainwright

TIPRANKS
·
15 Apr

BridgeBio Pharma, Inc. : H.c. Wainwright Raises Target Price to $53 From $49

THOMSON REUTERS
·
15 Apr

Press Release: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
12 Apr

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

Dow Jones
·
11 Apr

BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial

MT Newswires Live
·
01 Apr

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients With Variant Attr-Cm

THOMSON REUTERS
·
31 Mar

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

GlobeNewswire
·
31 Mar

BridgeBio Pharma Initiated at Buy by Redburn Atlantic

Dow Jones
·
31 Mar

Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target

MT Newswires Live
·
31 Mar

Piper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
31 Mar

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy

Insider Monkey
·
30 Mar

BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition

MT Newswires Live
·
27 Mar

BRIEF-Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM

Reuters
·
27 Mar

BridgeBio announces Japanese MHLW approved acoramidis for treating ATTR-CM

TIPRANKS
·
27 Mar

BridgeBio Pharma- Will Receive a $30 Mln Milestone Payment Upon Approval in Japan

THOMSON REUTERS
·
27 Mar

Beyonttra™ (Acoramidis), the First Near-Complete Ttr Stabilizer (≥90%), Approved in Japan to Treat Attr-Cm

THOMSON REUTERS
·
27 Mar

BridgeBio Pharma Inc - Will GET Royalties in Low Double Digits on Sales of Acoramidis in Japan

THOMSON REUTERS
·
27 Mar